Travel advice for vaccinations: Essential details for travelers regarding the Chikungunya virus
As summer approaches and travel plans are made, it's essential for travelers to be aware of ongoing Chikungunya outbreaks in various parts of the world. The British Standing Committee on Vaccination (STIKO) has recommended Chikungunya vaccines for those aged 12 and older, especially those planning extended stays or repeated short trips to endemic areas, and those aged 60 and older or with severe underlying conditions.
Good mosquito protection remains crucial even with vaccination, as mosquitoes can transmit other diseases. The World Health Organization (WHO) has issued a warning about the global spread of the Chikungunya virus.
Two Chikungunya vaccines, Ixchiq and Vimkunya, are now approved in the EU. A single dose of either vaccine is sufficient to achieve basic immunity, and it is still possible to get vaccinated even shortly before travel. However, if less than two weeks remain between vaccination and travel, protection may not yet be fully established.
As of June 2025, countries with reported Chikungunya outbreaks include Bolivia, Réunion Island, France, and Italy. In Bolivia, an accelerating outbreak has been reported, with 3,863 cases this year and 505 cases in 2024. The outbreak is centered in Bolivia’s Santa Cruz department, prompting a Level 2 Travel Health Advisory by the US Centers for Disease Control and Prevention (CDC) as of June 26, 2025.
Réunion Island has reported 54,233 confirmed autochthonous Chikungunya cases since the start of 2025. This indicates a significant ongoing outbreak there. France has confirmed 30 local chikungunya cases in 12 different administrative regions by mid-July 2025, including a cluster of 13 cases in Salon-de-Provence. Italy reported its first local chikungunya case since 2017 in Piacenza province (Emilia-Romagna region) in 2025.
Other countries are considered at risk but have not reported active outbreaks in the data available. These include Brazil, Colombia, India, Mexico, Nigeria, Pakistan, the Philippines, and Thailand. No local chikungunya transmission has been reported in the United States since 2019.
To protect themselves from Chikungunya infection, travelers can wear long and light clothing, use insect repellent containing at least 30% DEET, and protect windows and doors with screens and use mosquito nets over beds. It's also recommended to seek travel medical advice in advance to determine which vaccine is suitable and to discuss individual risk factors.
Chikungunya infection symptoms usually appear 4 to 7 days after transmission, and include sudden fever, joint pain, skin rash, chills, and headache. Joint pain from Chikungunya can persist for weeks, months, or even years. There is no specific treatment for Chikungunya; only symptoms can be relieved with pain medication.
In summary, confirmed ongoing outbreaks as of June 2025 are notable in Bolivia, Réunion Island, France, and Italy. Other countries are considered at risk but have not reported active outbreaks in the data available. Travelers are advised to take necessary precautions and seek travel medical advice to ensure a safe and healthy trip.
[1]
- Science plays a significant role in combating Chikungunya outbreaks, providing data for tracking and understanding the disease spread.
- In the context of workplace wellness, employers should educate employees about the risks of Chikungunya and provide necessary measures for protection during travel.
- Medical conditions like chronic diseases, immune disorders, and neurological disorders could make individuals more susceptible to complications from Chikungunya.
- Environmental science helps identify areas that are conducive to mosquito breeding, aiding in disease prevention and management strategies.
- Mental health affects an individual's response to health challenges, including Chikungunya infection, and should be considered when addressing the disease on a global scale.
- The finance industry can play a crucial role in funding research, developing therapies, and treatments for Chikungunya and other diseases.
- Energy-efficient manufacturing processes could lead to cost savings that can be allocated towards health initiatives, such as Chikungunya research and prevention measures.
- Climate change can impact the growth and survival of mosquitoes, which in turn can influence disease transmission and expansion.
- In the realm of health and wellness, promoting fitness and exercise, along with proper nutrition, can bolster immune systems and enhance the body's ability to fight off Chikungunya.
- Eyes, ears, and skin can be affected by a variety of medical conditions during Chikungunya infection, necessitating ongoing monitoring in these areas of health.
- Aging populations may have different responses to Chikungunya, as well as unique risk factors that healthcare providers must consider when treating the disease.
- Regardless of gender, men's and women's health may be impacted by Chikungunya, and specific attention should be paid to addressing any sex-specific symptoms or concerns.
- The new vaccines Ixchiq and Vimkunya offer a promising approach to addressing the Chikungunya outbreak, but their long-term efficacy and safety remain to be determined.
- The manufacturing industry can assist in accelerating the production and distribution of Chikungunya vaccines to those who need them most.
- Supporting mental health is crucial during the stress and uncertainty of Chikungunya outbreaks, as anxiety and depression can have lasting effects on an individual's wellbeing.
- Men's health concerns such as prostate health and sexual function may be impacted during and after Chikungunya infection, necessitating ongoing research and care.
- Women's health issues like pregnancy, breastfeeding, and reproductive health should be considered in the context of Chikungunya transmission and treatment.
- Parenting and childcare during a Chikungunya outbreak can present unique challenges, as parents must balance the needs of their children and the threat of the disease.
- Weight management is integral to overall health and can influence an individual's susceptibility to Chikungunya infection, as well as the severity of symptoms experienced.
- Cardiovascular health is essential for managing the body's response to Chikungunya and supporting a swift recovery.
- The innovation and growth in the industry contribute to the development of new solutions for Chikungunya vaccine production, distribution, and storage.
- Medicare coverage and Medicaid programs play a vital role in ensuring that Chikungunya vaccines and necessary treatments are affordable and accessible for all Americans.
- CBD, derived from cannabis, is being explored as a potential treatment for Chikungunya-related symptoms due to its anti-inflammatory properties.
- Collaboration among governments, health organizations, and the private sector is essential for understanding and addressing the complex challenges posed by the Chikungunya virus.
- Venture capitalists can invest in and support promising research efforts to develop novel Chikungunya vaccines and therapies.
- Personal finance and wealth management strategies can help travelers plan for health-related expenses while overseas, including purchasing Chikungunya vaccines and managing healthcare costs.
- Banking and insurance institutions can provide resources and protection for travelers by offering travel insurance policies that cover Chikungunya-related expenses.
- Fintech platforms can facilitate the rapid and secure transfer of funds for Chikungunya-related expenses, such as vaccine and treatment costs, in regions where traditional banking options are limited.
